Searched for: subject%3A%22Liver%22
(1 - 20 of 358)

Pages

document
Grinberg, M. (author), Stöber, R.M. (author), Edlund, K. (author), Rempel, E. (author), Godoy, P. (author), Reif, R. (author), Widera, A. (author), Madjar, K. (author), Schmidt-Heck, W. (author), Marchan, R. (author), Sachinidis, A. (author), Spitkovsky, D. (author), Hescheler, J. (author), Carmo, H. (author), Arbo, M.D. (author), van de Water, B. (author), Wink, S. (author), Vinken, M. (author), Rogiers, V. (author), Escher, S. (author), Hardy, B. (author), Mitic, D. (author), Myatt, G. (author), Waldmann, T. (author), Mardinoglu, A. (author), Damm, G. (author), Seehofer, D. (author), Nüssler, A. (author), Weiss, T.S. (author), Oberemm, A. (author), Lampen, A. (author), Schaap, M.M. (author), Luijten, M. (author), van Steeg, H. (author), Thasler, W.E. (author), Kleinjans, J.C.S. (author), Stierum, R.H. (author), Leist, M. (author), Rahnenführer, J. (author), Hengstler, J.G. (author)
Correction to: Arch Toxicol (2014) 88:2261–2287 https://doi.org/10.1007/s00204-014-1400-x.
article 2022
document
Ostendorf, R. (author)
The Organ-on-a-Chip Early Research Program (ERP) has enabled TNO to offer a number of state-of-the-art technologies to help pharmaceutical and biotech companies advance and accelerate drug development. An accurate, viable alternative to animal testing, on-a-chip technologies model the workings of human tissue and accelerate compound development...
other 2022
document
van Loy, T. (author), de Jonghe, S. (author), Castermans, K. (author), Dheedene, W. (author), Stoop, R. (author), Verschuren, L. (author), Versele, M. (author), Chaltin, P. (author), Luttun, A. (author), Schols, D. (author)
Atypical chemokine receptor 3 (ACKR3, formerly CXC chemokine receptor 7) is a G protein-coupled receptor that recruits β-arrestins, but is devoid of functional G protein signaling after receptor stimulation. In preclinical models of liver and lung fibrosis, ACKR3 was previously shown to be upregulated after acute injury in liver sinusoidal and...
article 2022
document
van Trijp, M.P.H. (author), Schutte, S. (author), Esser, D. (author), Wopereis, S. (author), Hoevenaars, F.P.M. (author), Hooiveld, G.J.E.J. (author), Afman, L.A. (author)
Background: Whole grain wheat (WGW) products are advocated as a healthy choice when compared with refined wheat (RW). One proposed mechanism for these health benefits is via the microbiota, because WGW contains multiple fibers. WGW consumption has been proposed to ameliorate nonalcoholic fatty liver disease, in which microbiota might play a role...
article 2021
document
Stevens, L.J. (author), Zhu, A.Z.X. (author), Chothe, P.P. (author), Chowdhury, S.K. (author), Donkers, J.M. (author), Vaes, W.H.J. (author), Knibbe, C.A.J. (author), Alwayn, I.P.J. (author), van de Steeg, E. (author)
There is a lack of translational preclinical models that can predict hepatic handling of drugs. In this study we aimed to evaluate the applicability of normothermic machine perfusion (NMP) of porcine livers as a novel ex vivo model to predict hepatic clearance, biliary excretion and plasma exposure of drugs. For this evaluation we dosed...
article 2021
document
Gart, E. (author), van Duyvenvoorde, W. (author), Toet, K. (author), Caspers, M.P.M. (author), Verschuren, L. (author), Nielsen, M.J. (author), Leeming, D.J. (author), Lima, E.S. (author), Menke, A. (author), Hanemaaijer, R. (author), Keijer, J. (author), Salic, K. (author), Kleemann, R. (author), Morrison, M.C. (author)
In obesity-associated non-alcoholic steatohepatitis (NASH), persistent hepatocellular damage and inflammation are key drivers of fibrosis, which is the main determinant of NASH-associated mortality. The short-chain fatty acid butyrate can exert metabolic improvements and anti-inflammatory activities in NASH. However, its effects on NASH...
article 2021
document
van den Hoek, A.M. (author), de Jong, J.C.B.C. (author), Worms, N. (author), van Nieuwkoop, A. (author), Voskuilen, M. (author), Menke, A.L. (author), Lek, S. (author), Caspers, M.P.M. (author), Verschuren, L. (author), Kleemann, R. (author)
Background. Non-alcoholic steatohepatitis (NASH) has become one of the most common liver diseases and is still without approved pharmacotherapy. Lifestyle interventions using exercise and diet change remain the current treatment of choice and even a small weight loss (5–7%) can already have a beneficial effect on NASH. However, the underlying...
article 2021
document
Stevens, L.J. (author), Donkers, J.M. (author), Dubbel, J. (author), Vaes, W.H.J. (author), van de Steeg, E. (author), Knibbe, C.A.J. (author), Alwayn, I.P.J. (author), van de Steeg, E. (author)
To predict the absorption, distribution, metabolism and excretion (ADME) profile of candidate drugs a variety of preclinical models can be applied. The ADME and toxicological behavior of newly developed drugs are often investigated prior to assessment in humans, which is associated with long time-lines and high costs. Therefore, good predictions...
article 2020
document
Abe, N. (author), Kato, S. (author), Tsuchida, T. (author), Sugimoto, K. (author), Saito, R. (author), Verschuren, L. (author), Kleemann, R. (author), Oka, K. (author)
Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disease in the Western world. Currently, only a few animal models show both the metabolic and histological features of human NASH. We aimed to explore murine NASH models in a time dependent manner that exhibit metabolic, histological and transcriptomic hallmarks of human NASH. For this...
article 2019
document
Salic, K. (author), Gart, E. (author), Verschuren, L. (author), van Duyvenvoorde, W. (author), Wong, K.E. (author), Keijer, J. (author), Bobeldijk-Pastorova, I. (author), Wielinga, P.Y. (author), Kleemann, R. (author)
Obesity characterized by adiposity and ectopic fat accumulation is associated with the development of non-alcoholic fatty liver disease (NAFLD). Treatments that stimulate lipid utilization may prevent the development of obesity and comorbidities. This study evaluated the potential anti-obesogenic hepatoprotective effects of combined treatment...
article 2019
document
Gart, E. (author), Souto Lima, E. (author), Schuren, F, (author), de Ruiter, C.G.F. (author), Attema, J. (author), Verschuren, L. (author), Keijer, J. (author), Salic, K. (author), Morrison, M.C. (author), Kleemann, R. (author)
Development of non-alcoholic fatty liver disease (NAFLD) is linked to obesity, adipose tissue inflammation, and gut dysfunction, all of which depend on diet. So far, studies have mainly focused on diet-related fecal microbiota changes, but other compartments may be more informative on host health. We present a first systematic analysis of...
article 2019
document
Hoevenaars, F.P.M. (author), Esser, D. (author), Schutte, S. (author), Priebe, M.G. (author), Vonk, R.J. (author), van den Brink, W.J. (author), van der Kamp, J.W. (author), Stroeve, J.H.M. (author), Afman, L.A. (author), Wopereis, S. (author)
Background. Whole grain wheat (WGW) consumption is associated with health benefits in observational studies. However, WGW randomized controlled trial (RCT) studies show mixed effects. Objectives. The health impact of WGW consumption was investigated by quantification of the body's resilience, which was defined as the “ability to adapt to a...
article 2019
document
Schutte, S. (author), Esser, D. (author), Hoevenaars, F.P.M. (author), Hooiveld, G.J.E.J. (author), Priebe, M.G. (author), Vonk, R.J. (author), Wopereis, S. (author), Afman, L.A. (author)
Background: Whole-grain wheat (WGW) is described as nutritionally superior to refined wheat (RW) and thus advocated as the healthy choice, although evidence from intervention studies is often inconsistent. The liver, as the central organ in energy metabolism, might be an important target organ for WGW interventions. Objective: The aim of this...
article 2018
document
van Groen, B.D. (author), van de Steeg, E. (author), Mooij, M.G. (author), van Lipzig, M.M.H. (author), de Koning, B.A.E. (author), Verdijk, R.M. (author), Wortelboer, H.M. (author), Gaedigk, R. (author), Bi, C. (author), Leeder, S. (author), van Schaik, R.H.N. (author), van Rosmalen, J. (author), Tibboel, D. (author), Vaes, W.H. (author), de Wildt, S.N. (author)
Background Hepatic membrane transporters are involved in the transport of many endogenous and exogenous compounds, including drugs. We aimed to study the relation of age with absolute transporter protein expression in a cohort of 62 mainly fetus and newborn samples. Methods Protein expressions of BCRP, BSEP, GLUT1, MCT1, MDR1, MRP1, MRP2, MRP3,...
article 2018
document
Morrison, M.C. (author), Kleemann, R. (author), van Koppen, A. (author), Hanemaaijer, R. (author), Verschuren, L. (author)
Introduction: It is generally accepted that metabolic inflammation in the liver is an important driver of disease progression in NASH and associated matrix remodeling/fibrosis. However, the exact molecular inflammatory mechanisms are poorly defined in human studies. Investigation of key pathogenic mechanisms requires the use of pre-clinical...
article 2018
document
Heringa, M.B. (author), Peters, R.J.B. (author), Bleys, R.L.A.W. (author), van der Lee, M.K. (author), Tromp, P.C. (author), van Kesteren, P.C.E. (author), van Eijkeren, J.C.H. (author), Undas, A.K. (author), Oomen, A.G. (author), Bouwmeester, H. (author)
Background: Titanium dioxide (TiO2) is produced at high volumes and applied in many consumer and food products. Recent toxicokinetic modelling indicated the potential of TiO2 to accumulate in human liver and spleen upon daily oral exposure, which is not routinely investigated in chronic animal studies. A health risk from nanosized TiO2 particle...
article 2018
document
Carmany, D. (author), Walz, A.J. (author), Hsu, F.L. (author), Benton, B. (author), Burnett, D. (author), Gibbons, J. (author), Noort, D. (author), Glaros, T. (author), Sekowski, J.W. (author)
Organophosphorus (OP) nerve agents continue to be a threat at home and abroad during the war against terrorism. Human exposure to nerve agents such as VX results in a cascade of toxic effects relative to the exposure level including ocular miosis, excessive secretions, convulsions, seizures, and death. The primary mechanism behind these overt...
article 2017
document
Leist, M. (author), Ghallab, A. (author), Graepel, R. (author), Marchan, R. (author), Hassan, R. (author), Bennekou, S.H. (author), Limonciel, A. (author), Vinken, M. (author), Schildknecht, S. (author), Waldmann, T. (author), Danen, E. (author), van Ravenzwaay, B. (author), Kamp, H. (author), Gardner, I. (author), Godoy, P. (author), Bois, F.Y. (author), Braeuning, A. (author), Reif, R. (author), Oesch, F. (author), Drasdo, D. (author), Höhme, S. (author), Schwarz, M. (author), Hartung, T. (author), Braunbeck, T. (author), Beltman, J. (author), Vrieling, H. (author), Sanz, F. (author), Forsby, A. (author), Gadaleta, D. (author), Fisher, C. (author), Kelm, J. (author), Fluri, D. (author), Ecker, G. (author), Zdrazil, B. (author), Terron, A. (author), Jennings, P. (author), van der Burg, B. (author), Dooley, S. (author), Meijer, A.H. (author), Willighagen, E. (author), Martens, M. (author), Evelo, C. (author), Mombelli, E. (author), Taboureau, O. (author), Mantovani, A. (author), Hardy, B. (author), Koch, B. (author), Escher, S. (author), van Thriel, C. (author), Cadenas, C. (author), Kroese, D. (author), van de Water, B. (author), Hengstler, J.G. (author)
Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event...
article 2017
document
Wopereis, S. (author), Stroeve, J.H.M. (author), Stafleu, A. (author), Bakker, G.C.M. (author), Burggraaf, J. (author), van Erk, M.J. (author), Pellis, L. (author), Boessen, R. (author), Kardinaal, A.A.F. (author), van Ommen, B. (author)
Background: A key feature of metabolic health is the ability to adapt upon dietary perturbations. Recently, it was shown that metabolic challenge tests in combination with the new generation biomarkers allow the simultaneous quantification of major metabolic health processes. Currently, applied challenge tests are largely non-standardized. A...
article 2017
document
Hoeke, G. (author), Wang, Y. (author), van Dam, A.D. (author), Mol, M. (author), Gart, E. (author), Klop, H.G. (author), van den Berg, S.M. (author), Pieterman, E.H. (author), Princen, H.M.G. (author), Groen, A.K. (author), Rensen, P.C.N. (author), Berbée, J.F.P. (author), Boon, M.R. (author)
Background and aims Activation of brown adipose tissue (BAT) reduces both hyperlipidemia and atherosclerosis by increasing the uptake of triglyceride-derived fatty acids by BAT, accompanied by formation and clearance of lipoprotein remnants. We tested the hypothesis that the hepatic uptake of lipoprotein remnants generated by BAT activation...
article 2017
Searched for: subject%3A%22Liver%22
(1 - 20 of 358)

Pages